What appetite‑suppressing medications are available for adult patients seeking weight loss?

Appetite-Suppressing Medications for Weight Loss

For adults seeking weight loss, semaglutide 2.4 mg should be prioritized as first-line pharmacotherapy due to its superior efficacy (11.4% greater weight loss vs placebo) and favorable impact on cardiometabolic outcomes 1, 2.

Medication Hierarchy Based on Efficacy

The 2022 AGA guidelines provide a clear framework for selecting appetite-suppressing medications, with all agents recommended as adjuncts to lifestyle modifications 1:

Tier 1: GLP-1 Receptor Agonists (Highest Efficacy)

• Semaglutide 2.4 mg (subcutaneous, weekly): 11.4% greater weight loss compared to placebo; may be prioritized over other medications for most patients due to magnitude of benefit 1, 2

  • Glucoregulatory benefits; approved for type 2 diabetes
  • Common adverse effects: nausea (28-44%), diarrhea (21-30%), constipation (11-24%)
  • Gradual dose titration mitigates GI side effects
  • Monitor for pancreatitis and gallbladder disease risk 1

• Liraglutide 3.0 mg (subcutaneous, daily): 4.7% greater weight loss compared to placebo 1, 2

  • Similar benefits and side effect profile to semaglutide
  • Alternative if weekly injection not preferred

Tier 2: Combination Agents (Moderate-High Efficacy)

• Phentermine-topiramate ER: 8.0% greater weight loss compared to placebo 1, 2

  • Preferentially use in patients with comorbid migraines (topiramate treats migraines)
  • Avoid in cardiovascular disease and uncontrolled hypertension
  • Topiramate is teratogenic—women of childbearing potential require effective contraception
  • Monitor blood pressure and heart rate periodically 1

• Naltrexone-bupropion ER: 4.1% greater weight loss compared to placebo 1, 2

  • Consider for patients attempting smoking cessation or with comorbid depression
  • Contraindicated with seizure disorders and concurrent opiate use
  • Monitor blood pressure/heart rate, especially first 12 weeks 1

Tier 3: Short-Term Sympathomimetics (Lower Efficacy)

• Phentermine monotherapy: 6.0 kg weight loss at 28 weeks; 46% achieved ≥5% weight loss 1, 3

  • FDA-approved for 12 weeks, but commonly used off-label long-term
  • Dosing: 15-37.5 mg daily in morning (or 8 mg up to 3 times daily)
  • Avoid in cardiovascular disease, uncontrolled hypertension, anxiety, or insomnia
  • Monitor blood pressure and heart rate 1

• Diethylpropion: Similar profile to phentermine

  • FDA-approved for 12 weeks; used off-label long-term
  • Same cardiovascular precautions as phentermine 1

Not Recommended

• Orlistat: AGA suggests against its use (only 3.1% greater weight loss) 1, 2
  • May consider only if patient highly values small benefit and tolerates GI side effects (oily spotting, urgency in >25% of patients)
  • Requires daily multivitamin with fat-soluble vitamins (A, D, E, K) taken 2 hours apart 1

Clinical Decision Algorithm

Step 1: Confirm patient has obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related complications AND inadequate response to lifestyle interventions 1

Step 2: Select medication based on patient profile:

• Most patients without contraindications → Semaglutide 2.4 mg
• Type 2 diabetes present → Semaglutide or liraglutide (dual benefit)
• Comorbid migraines → Phentermine-topiramate ER
• Smoking cessation or depression → Naltrexone-bupropion ER
• Cardiovascular disease/hypertension → Avoid sympathomimetics; use GLP-1 agonists
• Cost/access barriers → Phentermine (least expensive, but short-term approval)
• Seizure history → Avoid naltrexone-bupropion
• Concurrent opioid use → Avoid naltrexone-bupropion
• Women of childbearing potential → Avoid phentermine-topiramate (teratogenic); ensure contraception with any agent (all Category X) 3

Step 3: Initiate with gradual dose titration (especially GLP-1 agonists) to minimize GI side effects 1

Step 4: Monitor appropriately:

• Blood pressure and heart rate for sympathomimetics and combination agents
• Pancreatitis/gallbladder symptoms for GLP-1 agonists
• Weight loss response (expect 5-10% body weight loss in successful patients) 3

Critical Implementation Points

Obesity requires chronic treatment—medications generally need long-term use, not just 12 weeks 1. The FDA short-term approval for phentermine and diethylpropion reflects lack of long-term safety data, not evidence of harm with extended use 1, 3.

Tirzepatide (12.4% greater weight loss) shows even higher efficacy than semaglutide 2, but was not included in the 2022 AGA guidelines as it received FDA approval for obesity in 2023.

Common pitfall: Discontinuing medication after initial weight loss leads to weight regain. Frame obesity as a chronic disease requiring ongoing pharmacotherapy, similar to hypertension or diabetes 3.

Avoid weight-promoting medications when possible (e.g., certain antipsychotics, antidepressants, oral contraceptives, glucocorticoids) and substitute with weight-neutral alternatives 3.